Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute discusses strategies for treating 2nd line renal cell carcinoma (RCC) patients following I-O in the 1st line.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content